Literature DB >> 2392791

Pulmonary deposition of nebulised pentamidine isethionate: effect of nebuliser type, dose, and volume of fill.

M O'Doherty1, S Thomas, C Page, C Bradbeer, T Nunan, N Bateman.   

Abstract

An estimate of the absolute pulmonary deposition of nebulised pentamidine isethionate was obtained in nine patients with AIDS. Two nebuliser systems were compared, System 22 Mizer (Medic-Aid) and Respirgard II (Marquest), with 50 and 150 mg doses of pentamidine in a 3 ml solution driven by an air flow of 6 l/min with the patient in the sitting position. The 50 mg pentamidine dose was repeated with a 6 ml fill with both devices. The nebuliser cloud was labelled with technetium-99m human serum albumin (Ventocol) and lung deposition was measured with a gamma camera. Of the two nebulisers studied, System 22 Mizer delivered more drug to the lungs as a whole and to each individual lung region, including the peripheral and upper zones. For the 50 mg dose the mean (SEM) total pulmonary deposition with the 3 and the 6 ml fill respectively was 2.63 (0.34) and 3.71 (0.41) mg for the System 22 Mizer and 1.37 (0.26) and 1.45 (0.18) mg for the Respirgard II. For the 150 mg dose the System 22 Mizer delivered 7.16 (1.02) mg and the Respirgard II 4.34 (0.57) mg. Increasing the volume of fill from 3 to 6 ml increased pulmonary deposition with System 22 Mizer, and this was related to an increase in nebuliser output. Neither pulmonary deposition nor nebuliser output was increased by using a 6 ml solution in the Respirgard II. Increasing the volume of fill prolonged the time required for nebulisation with both nebulisers. The System 22 Mizer produced more nonpulmonary (gastric and oropharyngeal) deposition of drug, more frequent local adverse effects (cough, burning in the throat, and a metallic taste), and small reductions in lung function, particularly with the 150 mg pentamidine dose. Thus nebuliser type, volume of fill, and nebuliser dose affect the pulmonary deposition of pentamidine. A 300 mg dose of pentamidine via a Respirgard II is generally recommended as providing effective prophylaxis; our results suggest that similar pulmonary deposition can be produced with System 22 Mizer and 150 mg pentamidine. A clinical trial would be needed to show whether this regimen provides similar prophylactic benefit.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2392791      PMCID: PMC462530          DOI: 10.1136/thx.45.6.460

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  10 in total

1.  Differences in relative efficiency of nebulisers for pentamidine administration.

Authors:  M J O'Doherty; S Thomas; C Page; D Barlow; C Bradbeer; T O Nunan; N T Bateman
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

2.  Partial preservation of pancreatic beta-cell function in children with diabetes.

Authors:  R B Elliott; J R Crossley; C C Berryman; A G James
Journal:  Lancet       Date:  1981-07-04       Impact factor: 79.321

3.  Nebulised ribavirin for influenza B viral pneumonia in a ventilated immunocompromised adult.

Authors:  M Bell; J M Hunter; S M Mostafa
Journal:  Lancet       Date:  1988-11-05       Impact factor: 79.321

4.  Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.

Authors:  J M Littlewood; M G Miller; A T Ghoneim; C H Ramsden
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

5.  Treatment of experimental Legionnaires' disease by aerosol administration of rifampicin, ciprofloxacin, and erythromycin.

Authors:  R B Fitzgeorge; A Baskerville; A S Featherstone
Journal:  Lancet       Date:  1986-03-01       Impact factor: 79.321

6.  Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patients.

Authors:  P M Girard; R Landman; C Gaudebout; A Lepretre; P Lottin; C Michon; P De Truchis; S Matheron; F Camus; R Farinotti
Journal:  Lancet       Date:  1989-06-17       Impact factor: 79.321

7.  Evaluation of jet nebulisers for use with gentamicin solution.

Authors:  S P Newman; P G Pellow; M M Clay; S W Clarke
Journal:  Thorax       Date:  1985-09       Impact factor: 9.139

8.  The effects of preferential deposition of histamine in the human airway.

Authors:  R E Ruffin; M B Dolovich; R K Wolff; M T Newhouse
Journal:  Am Rev Respir Dis       Date:  1978-03

9.  Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

Authors:  A B Montgomery; R J Debs; J M Luce; K J Corkery; J Turner; E N Brunette; E T Lin; P C Hopewell
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

10.  Does 99Tcm human serum albumin alter the characteristics of nebulized pentamidine isethionate?

Authors:  M J O'Doherty; S Thomas; C Page; A R Clark; D Mitchell; E Heduan; T O Nunan; N T Bateman
Journal:  Nucl Med Commun       Date:  1989-07       Impact factor: 1.690

  10 in total
  9 in total

1.  Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients.

Authors:  Z Erjavec; G M Woolthuis; H G de Vries-Hospers; W J Sluiter; S M Daenen; B de Pauw; M R Halie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

Review 2.  The science of nebulised drug delivery.

Authors:  C O'Callaghan; P W Barry
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

3.  Quantification of technetium-99m lung radioactivity from planar images.

Authors:  N I Forge; P J Mountford; M J O'Doherty
Journal:  Eur J Nucl Med       Date:  1993-01

Review 4.  Aerosols for therapy and diagnosis.

Authors:  M J O'Doherty; R F Miller
Journal:  Eur J Nucl Med       Date:  1993-12

Review 5.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

6.  Antibiotic penetration into lung tissues.

Authors:  D Honeybourne
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

7.  Pulmonary deposition of a nebulised aerosol during mechanical ventilation.

Authors:  S H Thomas; M J O'Doherty; H M Fidler; C J Page; D F Treacher; T O Nunan
Journal:  Thorax       Date:  1993-02       Impact factor: 9.139

8.  Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers.

Authors:  S H Thomas; M J O'Doherty; A Graham; C J Page; P Blower; D M Geddes; T O Nunan
Journal:  Thorax       Date:  1991-10       Impact factor: 9.139

9.  Pulmonary deposition of aerosolised pentamidine using a new nebuliser: efficiency measurements in vitro and in vivo.

Authors:  P P Ferretti; A Versari; S I Gafà; M H Becquemin; E Barchi; D Serafini; M Roy; D Salvo; A Bouchikhi
Journal:  Eur J Nucl Med       Date:  1994-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.